Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help beat TB and HIV together?

NCT ID NCT04298905

Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a smartphone app and a tablet dashboard for community health workers to support people with both tuberculosis (TB) and HIV in South Africa. The app helps patients stay on track with their medications, while the dashboard alerts health workers if someone needs extra help. The goal is to improve treatment success and reduce deaths. About 62 adults with active TB and HIV are taking part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
smartphone app and community health worker dashboard
What this could lead to
If successful, this approach could improve treatment success rates for people with both TB and HIV in low-resource settings.
What could go wrong
This is a small, early-stage study with only 62 participants, so results may not apply broadly. The technology relies on consistent smartphone use and data connectivity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Mar 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any person 18 years of age or older with pulmonary TB * HIV positive * Outpatient TB treatment (including short course RR-TB treatment) or admission \< 30 days is expected Exclusion Criteria: * Unwilling or unable to provide informed consent, including inability to consent in one of the approved languages * Patients who require hospitalization for TB treatment at treatment initiation * Extrapulmonary or disseminated TB disease * Severe clinical presentation: BMI \< 18 kg/m2 or a person unable to stand/walk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence, patient are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease Patient Compliance pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adherence, patient Care coordination HIV/AIDS TB

Contacts and locations

Locations

  • Kelly Lowensen

    Baltimore, Maryland, 21224-3750, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.